---
schema_version: "secwatch.filing_event.v1"
accession: "0001658247-26-000022"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2026-04-10T23:59:59+00:00"
generated_at: "2026-05-15T06:40:59.956938+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Crinetics COO Jeff Knight resigns, enters consulting agreement at $400/hr

## Summary
- Jeff Knight resigned as Chief Development and Operating Officer effective April 10, 2026 (previously reported March 23, 2026).
- 1-year consulting agreement with $400/hour rate, max 20 hours/month, renewable for 6 months.
- Unvested restricted stock units and options forfeited; vested options exercisable three months after consulting ends.
- Consulting agreement includes a general release of all claims against the company.

## SEC filing metadata
- accession: 0001658247-26-000022
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2026-04-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000165824726000022/0001658247-26-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000165824726000022/crnx-20260410.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001658247-26-000022
- JSON: https://secwatch.observer/filing/0001658247-26-000022.json
- Plain text: https://secwatch.observer/filing/0001658247-26-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.